Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes¶

One-paragraph summary¶

Fourteen adults with undetectable baseline C-peptide received portal-vein zimislecel plus immunosuppression. All engrafted; 10/12 full-dose recipients were insulin-independent at one year. Serious neutropenia occurred in three and two participants died (PMID 40544428; NCT04786262).

Key findings¶

Renewable fully differentiated islets produced glucose-responsive function.
Early insulin-independence rate was high in a selected cohort.
Product function and immunosuppression cannot be separated in this design.

Limitations¶

Fourteen participants, uncontrolled interim analyses, short follow-up.
Rare and late harms cannot be characterized.
Systemic immunosuppression restricts risk-benefit applicability.

Why it matters¶

It is proof of functional renewable-cell replacement, while defining immunoprotection as the next bottleneck.

Cited by wiki pages¶

beta-cell replacement
clinical trials landscape
overview